Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.
Stefoni V, Casadei B, Bottelli C, Gaidano G, Ciochetto C, Cabras MG, Ansuinelli M, Argnani L, Broccoli A, Gandolfi L, Pellegrini C, Zinzani PL. Stefoni V, et al. Among authors: ciochetto c. Blood Cancer J. 2016 May 13;6(5):e425. doi: 10.1038/bcj.2016.29. Blood Cancer J. 2016. PMID: 27176801 Free PMC article.
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
Ibatici A, Pica GM, Nati S, Vitolo U, Botto B, Ciochetto C, Petrini M, Galimberti S, Ciabatti E, Orciuolo E, Zinzani PL, Cascavilla N, Guolo F, Fraternali Orcioni G, Carella AM. Ibatici A, et al. Among authors: ciochetto c. Br J Haematol. 2014 Mar;164(5):710-6. doi: 10.1111/bjh.12695. Epub 2013 Dec 17. Br J Haematol. 2014. PMID: 24344981 Free article. Clinical Trial.
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ciochetto C, Botto B, Passera R, Bellò M, Benevolo G, Boccomini C, Castellino A, Chiappella A, Freilone R, Nicolosi M, Orsucci L, Pecoraro C, Pregno P, Bisi G, Vitolo U. Ciochetto C, et al. Ann Hematol. 2018 Sep;97(9):1619-1626. doi: 10.1007/s00277-018-3328-3. Epub 2018 Apr 16. Ann Hematol. 2018. PMID: 29663029 Clinical Trial.
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A. Musso M, et al. Among authors: ciochetto c. Br J Haematol. 2016 Jan;172(1):111-21. doi: 10.1111/bjh.13803. Epub 2015 Oct 12. Br J Haematol. 2016. PMID: 26458240 Free PMC article.
PGNMID and anti-CD38 monoclonal antibody: a therapeutic challenge.
Rahbari E, Barreca A, Nicolino B, Ciochetto C, Piraina V, Maroni S, Deagostini MC, Patti R, Bertucci P, Savoldi S. Rahbari E, et al. Among authors: ciochetto c. G Ital Nefrol. 2022 Feb 16;39(1):2022-vol1. G Ital Nefrol. 2022. PMID: 35191627 Free article.